Rare Disease Therapies And Regulatory Hurdles Will Shape Long Term Outlook

Catalysts

About Stoke Therapeutics

Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide medicines designed to restore protein expression in severe genetic diseases such as Dravet syndrome and Autosomal Dominant Optic Atrophy.

What are the underlying business or industry changes driving this perspective?

• The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.
• Growing focus on value-based pricing and payer scrutiny for high-cost rare disease drugs, especially those backed initially by open-label and surrogate endpoint data, could compress net pricing power for zorevunersen and weigh on future net margins.
• Expansion into Autosomal Dominant Optic Atrophy with STK-002, while strategically aligned, introduces another long, high-risk development path in a slowly progressive ophthalmic disease. Proving clinically meaningful vision benefit may be difficult and could extend the time to any material revenue contribution.
• Increasing complexity and cost of global late-stage programs in neurology, including sham-controlled intrathecal studies and country-specific regulatory demands, is likely to drive continued operating expense growth faster than topline collaboration revenue. This could pressure operating margins and earnings.
• Reliance on larger partners for ex North America strategy in rare genetic diseases, amid a competitive landscape where big pharma is prioritizing its own neurology and genetic platforms, creates risk that milestone timing, co-funding levels, or commercial focus could fall short of expectations and temper long-term revenue and earnings leverage.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Stoke Therapeutics's revenue will decrease by 26.7% annually over the next 3 years.
• Analysts are not forecasting that Stoke Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Stoke Therapeutics's profit margin will increase from 19.7% to the average US Biotechs industry of 16.2% in 3 years.
• If Stoke Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $13.2 million (and earnings per share of $0.2) by about December 2028, down from $40.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 214.5x on those 2028 earnings, up from 44.9x today. This future PE is greater than the current PE for the US Biotechs industry at 21.6x.
• Analysts expect the number of shares outstanding to grow by 5.62% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.01%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• If the long duration Phase III EMPEROR trial fails to replicate the robust seizure and Vineland 3 cognition benefits seen in the smaller open label extension and natural history analyses, the perceived disease modifying profile of zorevunersen could be challenged, leading to lower than expected uptake and weaker long term revenue and earnings growth.
• Despite breakthrough therapy designation and extensive OLE data, the FDA or other regulators may insist on full Phase III results without granting any accelerated or earlier path to approval. This would delay commercialization beyond current expectations and extend the company’s cash burn, pressuring net margins and earnings.
• The collaboration with Biogen and Stoke’s growing internal commercial and medical affairs build out may not translate into efficient market access or reimbursement in rare disease markets where payers are increasingly demanding value based evidence. This could limit achievable pricing and compress future net margins and operating income.
• Long term safety findings, including the high incidence of CSF protein elevations and additional serious adverse events as dosing accumulates over many years, could change the current favorable safety profile and force dose limitations or label restrictions. This would reduce treated patient numbers and constrain revenue and earnings potential.
• The decision to expand the antisense platform into Autosomal Dominant Optic Atrophy with STK 002, based on encouraging but early nonhuman primate data, introduces additional clinical and regulatory risk. Any setbacks or failure to show clear vision benefit in this slowly progressive disease could undermine confidence in the broader platform, weigh on investor sentiment, and limit the company’s ability to grow revenue beyond Dravet syndrome.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $34.25 for Stoke Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $24.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $81.1 million, earnings will come to $13.2 million, and it would be trading on a PE ratio of 214.5x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $31.86, the analyst price target of $34.25 is 7.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.